<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>combination therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/combination-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 23 Jan 2026 14:24:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>combination therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Radiation: An Immune Modulator’s Role in Immunotherapy</title>
		<link>https://bioengineer.org/radiation-an-immune-modulators-role-in-immunotherapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 14:23:45 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[bu iki tedavinin b]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[Cancer Treatment Outcomes** * **Radiation Immune Modulation:** Ana konu]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[fraksiyon]]></category>
		<category><![CDATA[hacim) etkisi vurgulanıyor. * **Immune Modulation:** Radyasyonun bağışıklık sistemi üzerindeki temel etkisi (immünostimülasyon/immünosupresyon) ve me]]></category>
		<category><![CDATA[immune checkpoint blockade]]></category>
		<category><![CDATA[Immune Modulation]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket: **Radiation Immune Modulation]]></category>
		<category><![CDATA[parametrelerin (doz]]></category>
		<category><![CDATA[Predictive Biomarkers * **Radiation Therapy:** Ana konu]]></category>
		<category><![CDATA[Radiation Dose Fractionation]]></category>
		<category><![CDATA[Radiation Therapy]]></category>
		<category><![CDATA[Radiotherapy Immunotherapy Combination]]></category>
		<category><![CDATA[radyasyonun bağışıklık sistemini değiştirme etkisi. * **Radiotherapy Immunotherapy Combination:** Makalenin temel odağı]]></category>
		<guid isPermaLink="false">https://bioengineer.org/radiation-an-immune-modulators-role-in-immunotherapy/</guid>

					<description><![CDATA[Radiation therapy has long been a cornerstone in the treatment of various forms of cancer, but its role has recently evolved to encompass not just direct cytotoxic effects but also the modulation of the immune response. This dual action is of particular interest in the context of combining radiation therapy with immune checkpoint blockade (ICB), [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319851</post-id>	</item>
		<item>
		<title>Combining Intralesional Immunotherapy for Verruca Treatment</title>
		<link>https://bioengineer.org/combining-intralesional-immunotherapy-for-verruca-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 09:21:48 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[HPV tedavisi]]></category>
		<category><![CDATA[HPV treatment]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **intralesional immunotherapy]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **intralezyonel immünoterapi]]></category>
		<category><![CDATA[klinik sonuçlar**]]></category>
		<category><![CDATA[kombine dermatoloji tedavileri]]></category>
		<category><![CDATA[siğil tedavisi]]></category>
		<category><![CDATA[wart treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/combining-intralesional-immunotherapy-for-verruca-treatment/</guid>

					<description><![CDATA[In a groundbreaking study led by Nofal et al., researchers have delved into the intricate world of dermatology, focusing particularly on multiple verrucae, commonly known as warts. This research has brought to light a promising approach to treatment by examining the efficacy of combined intralesional immunotherapy. The project’s core hypothesis posits that amalgamating different therapeutic [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319716</post-id>	</item>
		<item>
		<title>Novel Triple Therapy for Neonatal Carbapenem Infections</title>
		<link>https://bioengineer.org/novel-triple-therapy-for-neonatal-carbapenem-infections/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 22 Jan 2026 16:43:10 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[antibiotic resistance]]></category>
		<category><![CDATA[Carbapenem-Resistant Enterobacteriaceae]]></category>
		<category><![CDATA[Carbapenemase-producing Enterobacteriaceae]]></category>
		<category><![CDATA[Case Report** * **Neonatal Infections:** Makalenin ana odağı yenidoğanlardaki enfeksiyonlar. * **Carbapenem-Resistant Enterobacteriaceae (CRE):** Tedavi edilen spesifik ve tehlikeli bakteri]]></category>
		<category><![CDATA[Case report** **Açıklama:** 1. **Neonatal carbapenem infections:** Makalenin ana konusu]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[İçeriğe uygun 5 etiket: **Neonatal carbapenem infections]]></category>
		<category><![CDATA[İçerik analizine dayanarak en uygun 5 etiket: **Neonatal Infections]]></category>
		<category><![CDATA[triple combination therapy]]></category>
		<category><![CDATA[yenidoğanlarda görülen karbapenem dirençli enfeksiyonlar. 2. **Triple combination therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/novel-triple-therapy-for-neonatal-carbapenem-infections/</guid>

					<description><![CDATA[In recent years, the rise of multidrug-resistant bacteria has become a pressing concern in the realm of pediatric medicine. Among these, carbapenemase-producing Enterobacteriaceae (CPE) poses a significant risk, particularly for vulnerable populations such as neonates. In a groundbreaking case report, researchers Wang and Tan delve into the complex treatment options available for this challenging class [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319366</post-id>	</item>
		<item>
		<title>Targeting cGAS–STING in Cancer: Opportunities and Challenges</title>
		<link>https://bioengineer.org/targeting-cgas-sting-in-cancer-opportunities-and-challenges/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jan 2026 04:56:42 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[cGAS-STING Yolu]]></category>
		<category><![CDATA[cGAS-STING'in kanser tedavisindeki rolü bu ba]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[İçeriğe göre en uygun 5 etiket: **Kanser İmmünoterapisi]]></category>
		<category><![CDATA[kanser immünoterapisinde bir strateji olarak ele alınıyor. * **]]></category>
		<category><![CDATA[Kişiselleştirilmiş Tedavi** * **Kanser İmmünoterapisi:** Makalenin temel konusu]]></category>
		<category><![CDATA[Kombinasyon Terapisi]]></category>
		<category><![CDATA[Makale içeriğine uygun 5 etiket: **cGAS-STING Pathway]]></category>
		<category><![CDATA[Therapeutic Challenges** * **cGAS-STING Pathway:** Makalenin ana konusu bu sinyal yoludur. * **Cancer Immunotherapy:** cGAS-STING'in modülasyonu]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tümör mikroçevresi]]></category>
		<guid isPermaLink="false">https://bioengineer.org/targeting-cgas-sting-in-cancer-opportunities-and-challenges/</guid>

					<description><![CDATA[The cGAS–STING pathway has emerged as a pivotal mechanism in the landscape of immuno-oncology, particularly in its role in detecting tumor-derived DNA. This pathway initiates a cascade of immune responses that can either promote or suppress tumor growth, reflecting the dual nature of inflammatory signals within the tumor microenvironment. At its core, cyclic guanosine monophosphate [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318133</post-id>	</item>
		<item>
		<title>Girdin Silencing Boosts Mebendazole’s Ovarian Cancer Fight</title>
		<link>https://bioengineer.org/girdin-silencing-boosts-mebendazoles-ovarian-cancer-fight/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 29 Dec 2025 09:20:23 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[girdin silencing]]></category>
		<category><![CDATA[mebendazole]]></category>
		<category><![CDATA[microtubule disruption]]></category>
		<category><![CDATA[ovarian cancer therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/girdin-silencing-boosts-mebendazoles-ovarian-cancer-fight/</guid>

					<description><![CDATA[A groundbreaking study emerging from the frontline of ovarian cancer research has unveiled a novel combinatorial therapeutic approach that could redefine treatment paradigms. By harnessing the potential of mebendazole, a widely used anti-parasitic agent, and coupling it with the targeted silencing of the protein girdin, scientists have opened a promising new avenue in cancer therapy. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">312024</post-id>	</item>
		<item>
		<title>Dual IGF-1R and Autophagy Block Halts Cancer Spread</title>
		<link>https://bioengineer.org/dual-igf-1r-and-autophagy-block-halts-cancer-spread/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 26 Dec 2025 11:51:47 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[autophagy blockade]]></category>
		<category><![CDATA[cancer cell survival mechanisms]]></category>
		<category><![CDATA[colorectal cancer metastasis]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[IGF-1R inhibition]]></category>
		<category><![CDATA[Metastasis prevention]]></category>
		<guid isPermaLink="false">https://bioengineer.org/dual-igf-1r-and-autophagy-block-halts-cancer-spread/</guid>

					<description><![CDATA[In a groundbreaking advance poised to reshape the therapeutic landscape of colorectal cancer, researchers Mahgoub, Bajbouj, Ahmed, and colleagues have elucidated a novel combinatorial strategy that effectively prevents metastasis. Published in Medical Oncology in 2026, this study reveals how simultaneous inhibition of the insulin growth factor 1 receptor (IGF-1R) and autophagy pathways can stymie the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">311351</post-id>	</item>
		<item>
		<title>Transcription Co-Inhibition Boosts TB Drug Effectiveness</title>
		<link>https://bioengineer.org/transcription-co-inhibition-boosts-tb-drug-effectiveness/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 11 Dec 2025 19:14:00 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[AAP-SO2]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[Mycobacterium tuberculosis]]></category>
		<category><![CDATA[rifampicin resistance]]></category>
		<category><![CDATA[transcription co-inhibition]]></category>
		<guid isPermaLink="false">https://bioengineer.org/transcription-co-inhibition-boosts-tb-drug-effectiveness/</guid>

					<description><![CDATA[In the relentless battle against tuberculosis (TB), a disease that remains the leading cause of death from a single infectious agent worldwide, scientists have made a compelling breakthrough that could redefine therapeutic strategies. The bacterium Mycobacterium tuberculosis (Mtb), notorious for its resilience and increasing resistance to frontline drugs, has long been a formidable adversary in [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">306180</post-id>	</item>
		<item>
		<title>Cellular Reprogramming in Early Hormone-Positive Breast Cancer</title>
		<link>https://bioengineer.org/cellular-reprogramming-in-early-hormone-positive-breast-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 28 Nov 2025 15:47:49 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[anti-PD-1 immunotherapy]]></category>
		<category><![CDATA[cellular reprogramming]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: **hormone receptor-positive breast cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cellular-reprogramming-in-early-hormone-positive-breast-cancer/</guid>

					<description><![CDATA[In a groundbreaking study that could redefine therapeutic strategies for hormone receptor-positive breast cancer, researchers have uncovered profound cellular reprogramming occurring during combined anti-PD-1 immunotherapy and chemotherapy treatment in early-stage patients. This cutting-edge research sheds light on the intricate molecular interplay and adaptive mechanisms within tumor microenvironments, potentially opening new avenues for precision oncology and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">302852</post-id>	</item>
		<item>
		<title>New Two-Drug Combination Shows Promise in Enhancing Colorectal Cancer Treatment</title>
		<link>https://bioengineer.org/new-two-drug-combination-shows-promise-in-enhancing-colorectal-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 22 Oct 2025 17:34:35 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[colorectal cancer treatment]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[drug combination therapy]]></category>
		<category><![CDATA[drug resistance]]></category>
		<category><![CDATA[metabolic adaptation targeting]]></category>
		<category><![CDATA[Metabolic Reprogramming]]></category>
		<category><![CDATA[overcoming drug resistance]]></category>
		<category><![CDATA[preclinical cancer research]]></category>
		<category><![CDATA[preclinical oncology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-two-drug-combination-shows-promise-in-enhancing-colorectal-cancer-treatment/</guid>

					<description><![CDATA[In a groundbreaking advancement in the fight against colorectal cancer, researchers from the University of Barcelona have unveiled a promising new therapeutic strategy designed to overcome a key obstacle in treatment efficacy—drug resistance. Their latest study reveals that combining the drugs palbociclib and telaglenastat could effectively counteract the metabolic adaptations that colorectal cancer cells develop [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">285287</post-id>	</item>
	</channel>
</rss>
